--- title: Buy Afinitor (Everolimus) 5mg, 10mg Pills Online description: Afinitor (Everolimus) 5mg and 10mg pills is a trusted advanced therapy for specific health conditions. Order from our secure pharmacy for verified quality. type: product language: en url: https://medsforsale.net/buy-afinitor-online-en availability: in_stock price_min: 314.99 price_max: 1598.99 currency: USD offers: - name: 5mg x 7 pills price: 314.99 - name: 5mg x 14 pills price: 587.99 - name: 5mg x 28 pills price: 1119.99 - name: 10mg x 7 pills price: 454.99 - name: 10mg x 14 pills price: 839.99 - name: 10mg x 28 pills price: 1598.99 --- # Buy Afinitor (Everolimus) 5mg, 10mg Pills Online Afinitor, featuring the active ingredient Everolimus, is a potent kinase inhibitor originally developed by Novartis. It is utilized in the treatment of various advanced conditions, including certain types of kidney, breast, and neuroendocrine tumors, by slowing the growth and spread of specialized cells. It is intended for adults undergoing supervised clinical protocols. Our pharmacy provides a discreet and professional service to access Afinitor in 5mg and 10mg pills for your ongoing treatment needs. ## Pricing and Options | Dosage | Pack Size | Price (USD) | Price Per Pill | Status | | :--- | :--- | :--- | :--- | :--- | | **5mg** | 7 pills | **$314.99** | $45.00 | In Stock | | **5mg** | 14 pills | **$587.99** | $42.00 | In Stock | | **5mg** | 28 pills | **$1119.99** | $40.00 | In Stock | | **10mg** | 7 pills | **$454.99** | $65.00 | In Stock | | **10mg** | 14 pills | **$839.99** | $60.00 | In Stock | | **10mg** | 28 pills | **$1598.99** | $57.11 | In Stock | [Buy Now](https://medsforsale.net/buy-afinitor-online-en) ## Introduction Afinitor (generic name everolimus) is an oral, targeted therapy classified as a mammalian target of rapamycin (mTOR) inhibitor. It is manufactured by Novartis and supplied as film-coated tablets in strengths of 5 mg and 10 mg. Afinior is primarily indicated for the treatment of several advanced malignancies and certain non-cancer conditions where inhibition of the mTOR pathway can control abnormal cell growth. FDA-approved uses include advanced renal cell carcinoma, hormone-receptor-positive advanced breast cancer, neuroendocrine tumors of gastroenteropancreatic origin, and prophylaxis of organ rejection in renal transplant recipients. Off-label investigations have explored its role in other tumor types and rare diseases, always under specialist supervision. ## What is Afinitor? Afinitor is the brand formulation of everolimus, a synthetic derivative of the natural macrolide rapamycin. The drug belongs to the class of mTOR inhibitors, a subgroup of immunosuppressants and anticancer agents. Everolimus was first synthesized in the late 1990s and received its first regulatory approval in 2009 for organ transplantation. Novartis developed Afinitor for oncology indications, and the same active molecule is also marketed under names such as Zortress (transplant) and Certican (cardiac-allograft vasculopathy). The tablets contain the active ingredient everolimus together with inactive excipients (lactose monohydrate, povidone, magnesium stearate, and microcrystalline cellulose). The medication is supplied in blister packs that protect the product from moisture and light. ## How Afinitor Works Everolimus binds with high affinity to the intracellular protein FKBP-12 (FK506-binding protein). The resulting complex inhibits the activity of the serine-threonine kinase mTORC1 (mechanistic target of rapamycin complex 1). mTORC1 is a central regulator of cell growth, proliferation, protein synthesis, and angiogenesis. By blocking mTORC1, everolimus reduces downstream signaling through S6 kinase and 4E-BP1, leading to cell-cycle arrest (primarily at G1) and decreased tumor-associated angiogenic factors such as VEGF. In transplant patients, mTORC1 inhibition dampens T-cell proliferation, providing immunosuppression without the nephrotoxicity typical of calcineurin inhibitors. The drug’s pharmacokinetics show a Tmax of 1-2 hours after oral intake, a half-life of approximately 30 hours, and predominant hepatic metabolism via CYP3A4, with renal excretion accounting for a minor fraction of the dose. ## Conditions Treated with Afinitor - **Advanced renal cell carcinoma (RCC)** - Everolimus is approved after progression on a prior VEGF-targeted therapy. In the pivotal RECORD-1 trial, progression-free survival (PFS) improved from 1.9 months (placebo) to 4.9 months (everolimus). - **Hormone-receptor-positive, HER2-negative advanced breast cancer** - Used in combination with exemestane after failure of non-steroidal aromatase inhibitors. The BOLERO-2 study demonstrated a median PFS of 10.6 months versus 5.0 months with exemestane alone. - **Neuroendocrine tumors of gastro-enteropancreatic (GEP-NET) origin** - Approved for progressive, well-differentiated, non-functional tumors. The RADIANT-4 trial reported a median PFS of 11.0 months compared with 3.9 months for placebo. - **Renal transplant prophylaxis** - Used to prevent acute rejection in adult kidney-transplant recipients, often in combination with reduced-dose calcineurin inhibitors to limit nephrotoxicity. The common therapeutic theme is that each indication involves dysregulated mTOR signaling, which drives uncontrolled cellular proliferation or immune activation. ## Off-Label and Investigational Uses of Afinitor Although not formally approved, everolimus has been evaluated in several off-label contexts: - **Advanced pancreatic neuroendocrine tumors (PNET)** - Small phase II studies suggest disease stabilization, particularly after failure of somatostatin analogues. - **Tuberous sclerosis complex (TSC)-related subependymal giant cell astrocytomas (SEGA)** - Everolimus is FDA-approved for SEGA, but its use for other TSC manifestations (e.g., renal angiomyolipomas) is considered off-label. Clinical data indicate tumor shrinkage in up to 60 % of patients. - **Hormone-refractory prostate cancer** - Early trials showed modest PSA declines; however, larger phase III studies have not confirmed a survival benefit. - **Lymphangioleiomyomatosis (LAM)** - Although a rare lung disease, everolimus has been used experimentally to slow disease progression, with mixed results. All off-label uses should be undertaken only under the direct supervision of a qualified specialist. Regulatory agencies have not evaluated the risk-benefit profile for these indications, and insurance coverage is typically unavailable. ## Is Afinitor the Right Medication for You? Afinitor is most appropriate for adults who have: - Documented progression of advanced RCC, hormone-receptor-positive breast cancer, or GEP-NET after standard first-line therapy. - Received a renal transplant and require an mTOR-based immunosuppressive regimen, particularly when calcineurin-inhibitor toxicity is a concern. Patients with uncontrolled infections, significant hepatic impairment (Child-Pugh C), or known hypersensitivity to everolimus or any tablet excipient should not receive the drug. Additionally, women who are pregnant, planning pregnancy, or breastfeeding must avoid everolimus because of teratogenic potential. Clinicians often select Afinitor when the therapeutic goal is disease stabilization rather than curative intent, and when the patient can tolerate chronic oral therapy with regular laboratory monitoring (lipids, glucose, renal and hepatic function). ## Risks, Side Effects, and Interactions ### Common - **Mouth sores (stomatitis)** - reported in up to 45 % of patients; usually mild to moderate. - **Fatigue** - a frequent complaint, often improves with dose adjustment. - **Diarrhea** - may be managed with anti-diarrheal agents and hydration. - **Rash** - typically maculopapular, resolves with topical steroids. - **Hyperglycemia** - monitor fasting glucose; may require antidiabetic medication. ### Rare - **Pneumonitis** - non-infectious interstitial lung disease occurs in <5 % but can be severe; requires imaging and possible discontinuation. - **Peripheral edema** - usually mild, resolves after dose reduction. - **Hepatotoxicity** - isolated elevations of transaminases; monitor liver enzymes. ### Serious - **Infections** - opportunistic infections (e.g., Pneumocystis jirovecii, herpes zoster) are heightened; prophylactic antivirals may be indicated. - **Severe hyperglycemia or new-onset diabetes** - can lead to ketoacidosis if untreated. - **Serious hemorrhage** - especially when combined with anticoagulants. - **Nephrotoxicity** - rare but possible, particularly when used with other nephrotoxic agents. #### Drug-Drug Interactions - **Strong CYP3A4 inhibitors** (ketoconazole, clarithromycin, grapefruit juice) increase everolimus exposure → dose reduction recommended. - **Strong CYP3A4 inducers** (rifampin, carbamazepine, St. John’s wort) decrease exposure → consider dose increase or alternative therapy. - **Immunosuppressants** (tacrolimus, cyclosporine) have additive effects on infection risk; monitor trough levels closely. - **Anticoagulants** (warfarin, direct oral anticoagulants) may experience increased bleeding risk; periodic coagulation assessments advised. Patients should disclose all prescription, over-the-counter, and herbal products before initiating therapy. ## Use: Dosing, Missed Dose, Overdose - **Standard adult dosing** for oncology: 10 mg orally once daily, taken consistently at the same time each day, with or without food. Dose reductions to 5 mg may be required for toxicity. - **Renal transplant prophylaxis**: initial dose of 0.75 mg twice daily, titrated to target blood concentrations (3-8 ng/mL). - **Missed dose**: If a dose is forgotten within 12 hours, take it as soon as remembered. If more than 12 hours have passed, skip the missed dose and resume the regular schedule. Do not double-dose. - **Overdose**: Symptoms may include severe nausea, vomiting, diarrhea, and profound fatigue. Seek emergency medical attention. Supportive care (activated charcoal, fluid replacement) is the mainstay; there is no specific antidote. - **Administration considerations**: Store tablets at 20-25 °C (68-77 °F); protect from moisture and light. Alcohol does not directly affect absorption but can exacerbate hepatic toxicity; limit intake. Patients should avoid operating heavy machinery until they know how the medication affects their alertness. ## FAQ - **What should I do if I experience severe mouth sores while taking Afinitor?** • Apply a prescription-strength corticosteroid mouthwash and avoid spicy or acidic foods. If sores persist beyond two weeks, contact your clinician for possible dose adjustment. - **Can I travel internationally with Afinitor tablets?** • Yes. Carry the medication in its original packaging with a copy of the prescription label. Some countries require a doctor’s note; verify local regulations before departure. - **Does Afinitor interact with hormonal contraceptives?** • Everolimus does not reduce the efficacy of combined oral contraceptives, but the risk of venous thromboembolism may be slightly increased. Discuss alternative or additional contraceptive methods with your provider. - **How long does it take for blood levels of everolimus to reach steady state?** • Because of its ~30-hour half-life, steady-state concentrations are usually achieved after 7-10 days of consistent daily dosing. - **Are there specific dietary restrictions while on Afinitor?** • No strict restrictions, but high-fat meals can modestly increase absorption. Consistency is key; take the tablet with the same type of meal (or none) each day. - **What laboratory tests are required during treatment?** • Baseline and periodic (every 4-8 weeks) assessments of complete blood count, serum creatinine, liver enzymes, fasting lipid profile, and glucose are recommended. - **Is everolimus safe for patients with mild hepatic impairment?** • Mild (Child-Pugh A) impairment does not usually require dose changes, but close monitoring of liver enzymes is advised. - **Can I use over-the-counter antacids with Afinitor?** • Antacids containing aluminum or magnesium do not affect everolimus absorption and are generally safe. - **Why does my doctor order a CT scan after three months of therapy?** • Imaging evaluates tumor response (size reduction or stabilization) and helps determine whether continued therapy is beneficial. - **Does Afinitor affect pregnancy testing results?** • Everolimus does not interfere with standard hCG assays, but the drug is teratogenic and must be stopped before conception under medical supervision. ## Glossary **mTOR (mechanistic target of rapamycin)** : A protein kinase that regulates cell growth, proliferation, and survival; inhibition of mTOR disrupts these pathways. **Pharmacokinetics** : The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. **Stomatitis** : Inflammation of the oral mucosa resulting in painful sores, a common side effect of mTOR inhibitors. **Cytochrome P450 3A4 (CYP3A4)** : An enzyme in the liver responsible for metabolizing many drugs; inhibitors raise drug levels, while inducers lower them. ## Buying Afinitor from [our online pharmacy](https://medsforsale.net/buy-afinitor-online-en) Patients who face high out-of-pocket costs, limited local availability, or insurance barriers can obtain Afinitor through **[our online pharmacy](https://medsforsale.net/buy-afinitor-online-en)**. We source the medication from licensed, FDA-registered international suppliers, guaranteeing that each batch meets strict quality-control standards. By operating as a pharmacy-broker service, we are able to offer the generic everolimus tablets at prices close to manufacturing cost, reducing the financial burden for long-term therapy. Our fulfillment process emphasizes speed and discretion: standard airmail delivery typically arrives within three weeks, while express shipping is available in about seven days. All packages are sealed in tamper-evident, unbranded envelopes to protect privacy. Customers receive a tracking number and a confidential delivery confirmation, ensuring peace of mind throughout the shipping journey. Choosing **[our online pharmacy](https://medsforsale.net/buy-afinitor-online-en)** means you receive a reliable, affordable supply of Afinitor without compromising safety or confidentiality. ## Disclaimer The information presented about **Afinitor** is intended for general educational purposes and does not substitute professional medical advice. Treatment decisions, including those involving off-label applications, must be made under the guidance of a qualified healthcare professional. Readers are presumed to be mature individuals capable of evaluating health information responsibly. **[our online pharmacy](https://medsforsale.net/buy-afinitor-online-en)** provides access to **Afinitor** for people who may encounter limited availability through conventional pharmacies, insurance-based programs, or who seek cost-effective generic alternatives. Always discuss any medication changes with your physician before initiating, adjusting, or discontinuing therapy.